Youngshin Kwak, Head of Oscotec Research Institute: "We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years" [BioUSA] - Press Releases - Oscotec Inc.

August 24, 2026

Youngshin Kwak, Head of Oscotec Research Institute: “We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years” [BioUSA]

By: Oscotec 오스코텍 2026

Attachment File